Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: A placebo-controlled, parallel-group, dose-ranging study

Journal of Dermatological Treatment

Volumn 9, Issue 3, 1998, Pages 143-149

  Paul, E ^a   Berth Jones, J ^b   Ortonne, J P ^c   Stern, M ^d  

^a KLINIKUM NÜRNBERG   (Germany)

^b WALSGRAVE HOSPITAL   (United Kingdom)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Fexofenadine hydrochloride; H1 receptor antagonist; Pruritus; Terfenadine; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE;

ADULT; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM;

EID: 0031658657     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.3109/09546639809160545     Document Type: Article

References (21)

1. Barnetson RStC, Allergy and the skin. In: Lessof MK (ed) Allergy. Immunological and clinical aspects. John Wiley & Sons, New York, 1984, pp 219-52.
2. Warin RP, Food and factors in urticaria. J Hunt Nutr (1976) 30: 179-86.
3. O'Donnell BF, Lawlor F, Simpson J et al, The impact of chronic urticaria on the quality of life. Br J Dermatol (1997) 136: 197-201.
4. Grattan CEH, Francis DM, Hide M, Greaves MW, Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy (1991) 21: 695-704.
5. Hide M, Francis DM, Grattan CEH et al, Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med (1993) 328: 1599-604.
6. Mathews KP, The urticarias. Current concepts of pathogenesis and treatment. Drugs (1985) 30: 552-60.
7. Soter NA, Urticaria: current therapy. J Allergy Clin Immunol (1990) 86: 1009-14.
8. 1-receptor-antagonist drugs. N Engl J Med (1994) 330: 1663-70.
9. Markham A, Wagstaff AJ, Fexofenadine, Drugs (1998) 55 (2): 269-76.
10. Garteiz DA, Hook RH, Walker BJ, Okerholm RA, Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung (1982) 32: 1185-90.
11. Lippert C, Ling J, Brown P et al, Mass balance and pharmacokinetics of fexofenadine HCl in healthy, male volunteers. Pharm Res (1995) 12 (Suppl 9): S390 (abstract).
12. c). Allergy (1997) 52 (Suppl 37): 67 (abstract 195).
13. Tinkleman D, Falliers C, Bronsky E et al, Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis. J Allergy Clin Immunol (1996) 97: 435 (abstract).
14. Bernstein D, Schoenwetter W, Nathan R et al, Efficacy and safety of fexofenadine HCl for seasonal allergic rhinitis. Ann Allergy Asthma Immunol (1997) 79: 443-8.
15. Lindquist M, Edwards IR, Risks of non-sedating antihistamines. Lancet (1997) 349: 1322.
16. Russell T, Stolz M, Eller M et al, Acute and sub chronic dose tolerance of fexofenadine HCl in healthy male subjects. Ann Allergy Asthma Immunol (1996) 76(1): 27 (abstract).
17. Woosley RL, Chen Y, Freiman JP, Gillis RA, Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 269: 1532-6.
18. Greaves M, Antihistamine treatment: a patient self-assessment method in chronic urticaria. BMJ (1981) 283: 1435-6.
19. Bleehen SS, Thomas SE, Greaves MW et al, Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol (1987) 117: 81-8.
20. Janssens MML, Howarth PH, The antihistamines of the nineties. Clin Rev Allergy (1993) 11: 111-53.
21. Tanner LA, Reilly M, Meltzer EO et al, Evaluation of quality of life and health economic measures in patients treated with fexofenadine HCl for seasonal allergic rhinitis. Ann Allergy Asthma Immunol (1997) 78(1): 125 (abstract).